Analysis of indoleamine 2-3 dioxygenase (IDO1) expression in breast cancer tissue by immunohistochemistry
Hatem Soliman(Moffitt Cancer Center), Stefan Ambs(University of Maryland, Baltimore), Scott Antonia(Parker Institute for Cancer Immunotherapy), Harris G. Yfantis(University of Maryland, Baltimore), Tiffany H. Dorsey(Center for Cancer Research), Farah Khalil(University of South Florida), Bhupendra Rawal(Harvard University), Jimmy Fulp(Moffitt Cancer Center), Ji‐Hyun Lee(Gachon University), Alexis S. Lopez(Moffitt Cancer Center), Dong Hoon Lee(Korea University), Marylin M. Bui(Moffitt Cancer Center)
Cited by 103
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
|The Lancet Oncology|2016|1.3k